Last reply 1 year ago
Ocrelizumab – from Prof Giovannoni

Not the only drug, but one of the best available.

Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Not quite top dog, but clearly in the upper tier.



Results suggest that ocrelizumab has an efficacy superior to or comparable with all other currently approved DMTs across all endpoints analyzed, and a similar safety profile, indicating it offers a valuable package for the treatment of patients with RMS.”

Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.

1 year ago

I am really envious and wish I could get my hands on ocrevus. Read a lot on it and know Roche is coining it from this old cancer drug. I hope their licence expire soon so other geberics can enter the market. I am starting Aubagio tonight. Also saw tecfidera is better than aubagio. Aubagio is probably the best available drug in South Africa. I have been trying to get work in England for the past 2 years (before my diagnosis) but brexit and employment policies make it difficult.

1 year ago

Ocrelizumab is similar to the anti-cancer agent cladribine, which has been repurposed for MS as Mavenclad.

However, it is not a straight repurposing. My understanding is that the B-cell depletion mode of action was further developed by taking the learning from the likes of cladribine and rituximab for developing a humanised monoclonal antibody that is ocrelizumab, a novel agent developed to treat MS first.

The intersection of research between MS and cancer seems to be becoming increasingly blurred as the role of the B-Cells in both diseases has been the where research has been focused. The discoveries have definitely blurred the boundary, which is why so many cross-overs in drugs exist.

Wikipedia is nicely linked from one to the other and you can really get into a rabbit-hole of reading if you have 60 min!

I find it all so fascinating. The interferon and glatiramer-acetate drugs were the first to show a demonstrable slowing of progress and this new generation is much closer to halting disease progress in some. The stem cells are in their early days and I hope that before I am too old they will become mainstream enough that they are widely accessible.

Righto, proper work to do. Have a lovely week!



1 year ago

Great to see some solid science on this forum – keep it up!

1 year ago

@birdboy – What is your PhD in?

1 year ago

I study the impacts on environmental change on marine top predators – seabirds.

Join to reply to this post.

Become part of the community so you can chat, compare and learn from other MSers.